Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib plus abiraterone/prednisone versus placebo plus abiraterone/prednisone in first-line metastatic castration-resistant prostate cancer
NL-OMON54799Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of abemaciclib, abiraterone and prednisone in metastatic castration-resistant prostate cancer (mCRPC) and prostate cancer (PCa) (6 arms), sponsored by Eli Lilly and Company. Primary endpoints: Recommended Phase 2 dose and Radiographic progression-free survival. Started Nov 2018; status: active, not recruiting.
02
Drugs
abemaciclibabirateroneprednisone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON54799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54799.